ATLANTA – Abbvie Inc.'s vice president of oncology, Gary Gordon, told BioWorld that his firm aims to "restate the standard of care" in chronic lymphocytic leukemia (CLL), and the firm moved another step closer with full results from the phase III Murano trial, detailed in a late-breaking session at the American Society of Hematology meeting.